| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Journal of Lipid Research, Vol 29, 669-677, Copyright © 1988 by Lipid Research, Inc.
ARTICLES |
NA Le, JC Gibson and HN Ginsberg
Department of Biomathematics and Biostatistics, Mount Sinai School of Medicine, New York, NY.
Apolipoproteins C-II (apoC-II) and C-III (apoC-III) are distributed among all the major lipoprotein classes, particularly very low density (VLDL) and high density lipoproteins (HDL). We have determined concentrations of apoC-II and apoC-III in VLDL and HDL in subjects with a wide range of VLDL triglyceride and HDL cholesterol levels, and correlated these levels with fractional catabolic rates (FCR) of VLDL triglyceride and HDL apolipoprotein A-I (apoA-I). Both apoC-II and apoC- III levels increased in VLDL as VLDL apolipoprotein B (apoB) and triglyceride levels rose. The rate of rise of VLDL apoC-III, however, was approximately 3 times greater than that of apoC-II, and positive correlations were present between the ratio of VLDL apoC-III/apoC-II and both VLDL apoB (r = 0.59; P less than 0.01) and VLDL triglyceride (r = 0.70; P less than 0.005) levels. Univariate analysis demonstrated that the FCR for VLDL triglyceride was inversely related to the ratio of apoC-III/apoC-II in VLDL (r = -0.58; P less than 0.05), although this relationship was not significant in a multivariate analysis. In HDL, concentrations of apoC-III and apoA-I were correlated (r = 0.73; P less than 0.005) while no correlation was observed between apoC-II and apoA-I levels. Univariate analyses of HDL variables revealed inverse correlations between the concentration of apoC-III and the FCR for apoA- I (r = -0.67; P less than 0.005) and between the ratio of apoC-III/apoA- I and the FCR for apoA-I (r = -0.66; P less than 0.005). Multivariate analysis confirmed the latter relationship.(ABSTRACT TRUNCATED AT 250 WORDS)
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  J. S. Millar, M. E. Brousseau, M. R. Diffenderfer, P. H. R. Barrett, F. K. Welty, J. S. Cohn, A. Wilson, M. L. Wolfe, C. Nartsupha, P. M. Schaefer, et al. Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on VLDL apolipoprotein E metabolism J. Lipid Res., March 1, 2008; 49(3): 543 - 549. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. C. Chan, M. N. Nguyen, G. F. Watts, and P. H. R. Barrett Plasma Apolipoprotein C-III Transport in Centrally Obese Men: Associations with Very Low-Density Lipoprotein Apolipoprotein B and High-Density Lipoprotein Apolipoprotein A-I Metabolism J. Clin. Endocrinol. Metab., February 1, 2008; 93(2): 557 - 564. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. N. Nguyen, D. C. Chan, K. P. Dwyer, P. Bolitho, G. F. Watts, and P. H. R. Barrett Use of Intralipid for kinetic analysis of HDL apoC-III: evidence for a homogeneous kinetic pool of apoC-III in plasma J. Lipid Res., June 1, 2006; 47(6): 1274 - 1280. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Nowak, A. Helleboid-Chapman, H. Jakel, G. Martin, D. Duran-Sandoval, B. Staels, E. M. Rubin, L. A. Pennacchio, M.-R. Taskinen, J. Fruchart-Najib, et al. Insulin-Mediated Down-Regulation of Apolipoprotein A5 Gene Expression through the Phosphatidylinositol 3-Kinase Pathway: Role of Upstream Stimulatory Factor Mol. Cell. Biol., February 15, 2005; 25(4): 1537 - 1548. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Conde-Knape, K. Okada, R. Ramakrishnan, and N. S. Shachter Overexpression of apoC-III produces lesser hypertriglyceridemia in apoB-48-only gene-targeted mice than in apoB-100-only mice J. Lipid Res., December 1, 2004; 45(12): 2235 - 2244. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Cohn, R. Batal, M. Tremblay, H. Jacques, L. Veilleux, C. Rodriguez, O. Mamer, and J. Davignon Plasma turnover of HDL apoC-I, apoC-III, and apoE in humans: in vivo evidence for a link between HDL apoC-III and apoA-I metabolism J. Lipid Res., October 1, 2003; 44(10): 1976 - 1983. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Olin-Lewis, R. M. Krauss, M. La Belle, P. J. Blanche, P. H. R. Barrett, T. N. Wight, and A. Chait ApoC-III content of apoB-containing lipoproteins is associated with binding to the vascular proteoglycan biglycan J. Lipid Res., November 1, 2002; 43(11): 1969 - 1977. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. N. Ginsberg New Perspectives on Atherogenesis: Role of Abnormal Triglyceride-Rich Lipoprotein Metabolism Circulation, October 15, 2002; 106(16): 2137 - 2142. [Full Text] [PDF]
|
|
|
|
|
|
K. K. Berneis and R. M. Krauss Metabolic origins and clinical significance of LDL heterogeneity J. Lipid Res., September 1, 2002; 43(9): 1363 - 1379. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Jong, P. C. N. Rensen, V. E. H. Dahlmans, H. van der Boom, T. J. C. van Berkel, and L. M. Havekes Apolipoprotein C-III deficiency accelerates triglyceride hydrolysis by lipoprotein lipase in wild-type and apoE knockout mice J. Lipid Res., October 1, 2001; 42(10): 1578 - 1585. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. M. Dallinga-Thie, M. Groenendijk, R. N. H. H. C. Blom, T. W. A. De Bruin, and E. De Kant Genetic heterogeneity in the apolipoprotein C-III promoter and effects of insulin J. Lipid Res., September 1, 2001; 42(9): 1450 - 1456. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Talmud, L. Berglund, E. M. Hawe, D. M. Waterworth, C. R. Isasi, R. E. Deckelbaum, T. Starc, H. N. Ginsberg, S. E. Humphries, and S. Shea Age-Related Effects of Genetic Variation on Lipid Levels: The Columbia University BioMarkers Study Pediatrics, September 1, 2001; 108(3): e50 - 50. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Bard, M. A. Charles, I. Juhan-Vague, P. Vague, P. Andre, M. Safar, J. C. Fruchart, E. Eschwege, and o. b. o. t. BIGPRO Study Group Accumulation of Triglyceride-Rich Lipoprotein in Subjects With Abdominal Obesity : The Biguanides and the Prevention of the Risk of Obesity (BIGPRO) 1 Study Arterioscler. Thromb. Vasc. Biol., March 1, 2001; 21(3): 407 - 414. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Bonnet, J.-B. Ruidavets, J. Tuech, J. FerriÈres, X. Collet, J. Fauvel, P. Massip, and B. Perret Apoprotein C-III and E-Containing Lipoparticles Are Markedly Increased in HIV-Infected Patients Treated with Protease Inhibitors: Association with the Development of Lipodystrophy J. Clin. Endocrinol. Metab., January 1, 2001; 86(1): 296 - 302. [Abstract] [Full Text]
|
|
|
|
|
|
H. Liu, C. Labeur, C.-F. Xu, R. Ferrell, L. Lins, R. Brasseur, M. Rosseneu, K. M. Weiss, S. E. Humphries, and P. J. Talmud Characterization of the lipid-binding properties and lipoprotein lipase inhibition of a novel apolipoprotein C-III variant Ala23Thr J. Lipid Res., November 1, 2000; 41(11): 1760 - 1771. [Abstract] [Full Text]
|
|
|
|
|
|
Y.-J. Y. Wan, D. An, Y. Cai, J. J. Repa, T. Hung-Po Chen, M. Flores, C. Postic, M. A. Magnuson, J. Chen, K. R. Chien, et al. Hepatocyte-Specific Mutation Establishes Retinoid X Receptor alpha as a Heterodimeric Integrator of Multiple Physiological Processes in the Liver Mol. Cell. Biol., June 15, 2000; 20(12): 4436 - 4444. [Abstract] [Full Text]
|
|
|
|
|
|
E. Raspé, L. Madsen, A-M. Lefebvre, I. Leitersdorf, L. Gelman, J. Peinado-Onsurbe, J. Dallongeville, J-C. Fruchart, R. Berge, and B. Staels Modulation of rat liver apolipoprotein gene expression and serum lipid levels by tetradecylthioacetic acid (TTA) via PPAR{alpha} activation J. Lipid Res., November 1, 1999; 40(11): 2099 - 2110. [Abstract] [Full Text]
|
|
|
|
|
|
H. N. Hodis Triglyceride-Rich Lipoprotein Remnant Particles and Risk of Atherosclerosis Circulation, June 8, 1999; 99(22): 2852 - 2854. [Full Text] [PDF]
|
|
|
|
|
|
M. C. Jong, M. H. Hofker, and L. M. Havekes Role of ApoCs in Lipoprotein Metabolism : Functional Differences Between ApoC1, ApoC2, and ApoC3 Arterioscler. Thromb. Vasc. Biol., March 1, 1999; 19(3): 472 - 484. [Full Text] [PDF]
|
|
|
|
|
|
Y. Andersson, Z. Majd, A.-M. Lefebvre, G. Martin, A. V. Sechkin, V. Kosykh, J.-C. Fruchart, J. Najib, and B. Staels Developmental and Pharmacological Regulation of Apolipoprotein C-II Gene Expression : Comparison With Apo C-I and Apo C-III Gene Regulation Arterioscler. Thromb. Vasc. Biol., January 1, 1999; 19(1): 115 - 121. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Packard and J. Shepherd Lipoprotein Heterogeneity and Apolipoprotein B Metabolism Arterioscler. Thromb. Vasc. Biol., December 1, 1997; 17(12): 3542 - 3556. [Abstract] [Full Text]
|
|
|
|
|
|
W. J. Mack, R. M. Krauss, and H. N. Hodis Lipoprotein Subclasses in the Monitored Atherosclerosis Regression Study (MARS) : Treatment Effects and Relation to Coronary Angiographic Progression Arterioscler. Thromb. Vasc. Biol., May 1, 1996; 16(5): 697 - 704. [Abstract] [Full Text]
|
|
|
|
 |
|
 E. Raspe, H. Duez, P. Gervois, C. Fievet, J.-C. Fruchart, S. Besnard, J. Mariani, A. Tedgui, and B. Staels Transcriptional Regulation of Apolipoprotein C-III Gene Expression by the Orphan Nuclear Receptor RORalpha J. Biol. Chem., January 19, 2001; 276(4): 2865 - 2871. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Journal of Biological Chemistry |
| Molecular and Cellular Proteomics | ASBMB Today |
